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ABSTRACT
Background: A named patient program (NPP) was designed to provide patients with advanced soft-
tissue sarcoma (aSTS) access to pazopanib, a multitargeted tyrosine kinase inhibitor. The SPIRE study
was a retrospective chart review of participating patients.
Patients and methods: Eligibility criteria for the NPP and SPIRE mirrored those of the pivotal phase-III
study, PALETTE, which compared pazopanib with placebo in patients 18 years with aSTS and whose
disease had progressed during or following prior chemotherapy or were otherwise unsuitable for
chemotherapy. Outcomes of interest included treatment patterns, treatment duration, relative dose
intensity, progression-free survival (PFS), overall survival (OS), clinical benefit rate, adverse events (AEs)
and reasons for treatment discontinuation.
Results: A total of 211 patients were enrolled (median age 56 years; 60% female). Most patients
received pazopanib in second- and third-line therapy (28.0% and 28.4%, respectively), followed by
fourth line (19.0%) and fifth line (18.5%). The median duration of pazopanib treatment was 3.1
months (95% CI: 2.8–3.8), with a mean daily dose of 715mg equating to 92% of recommended dose.
Median OS was 11.1 months and clinical benefit rate was 46%. There was evidence of some clinical
benefit across most histological subtypes. At study end, 40% of patients were alive and of these, 18%
remained on pazopanib. Thirteen percent (13%) of patients discontinued pazopanib due to AEs.
Conclusions: The SPIRE study demonstrated activity of pazopanib in heavily pretreated aSTS patients
in a compassionate use setting. No new safety concerns were noted. Reassuringly, the relative dose
intensity of pazopanib was 92%.
ARTICLE HISTORY
Received 14 December 2016
Accepted 15 May 2017
Introduction
Sarcomas are a rare group of solid tumors and over 80% of
sarcomas are soft-tissue sarcomas (STS) [1,2]. STS include het-
erogeneous tumors, with over 40 malignant histological sub-
types (defined by the current version of the World Health
Organization’s histopathological classification) which can
occur throughout the body [2–4]. The heterogeneity of STS
makes treating this disease a particular challenge. Prognostic
factors for survival include: histological subtype and tumor
site; tumor size; grade; age; performance status, and the pres-
ence of nodal or distant metastases [3,5]. Based on these
factors, treatment options may include surgery, radiotherapy
and/or chemotherapy [6].
In locally advanced or metastatic disease, systemic therapy
plays an important role [5,6]. Initial chemotherapy usually con-
sists of an anthracycline with or without ifosfamide [5,6].
Treatment options in second line and beyond can vary accord-
ing to histological subtypes and there is no standard chemo-
therapy in second line and beyond for patients who have
progressed after an anthracycline-based treatment [5–7].
Pazopanib (VotrientVR ) has been approved for pretreated
advanced STS (aSTS) in the USA, Europe and in Japan and
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is indicated for the treatment of adult patients with select-
ive subtypes of aSTS who have received prior chemotherapy
for metastatic disease or who have progressed within 12
months after receiving adjuvant or neoadjuvant therapy.
The recommended starting dose of pazopanib is 800mg
once daily [8].
Pazopanib is an oral anticancer agent and a multitargeted
tyrosine kinase inhibitor, that targets VEGFR1,2,3, PDGFR
alpha and beta and KIT, thereby blocking tumor growth and
inhibiting angiogenesis [5,8–13]. Pazopanib has demonstrated
activity in patients with aSTS following prior therapy [10,11].
In the phase-III PALETTE study, pazopanib demonstrated a
significant advantage in median PFS compared with placebo,
4.6 months versus 1.6 months respectively (hazard ratio [HR]:
0.31, 95% CI: 0.24–0.40; p< .0001) [11]. Median OS was 12.5
months with pazopanib versus 10.7 months with placebo
(HR: 0.86, 95% CI: 0.67–1.11; p¼ .25) [11]. Pazopanib was well
tolerated, with the most common grade 3/4 adverse events
being fatigue (13.7%), increased alanine transaminase (ALT)
(9.6%) and lymphopenia (9.6%) [14].
This pazopanib NPP was launched during the pazopanib
regulatory review process, upon request by physicians follow-
ing the positive results of the PALETTE trial, to provide pazo-
panib treatment to appropriate patients with aSTS [13]. The
results obtained from the SPIRE study (Sarcoma named
PatIent progRamme chart rEview) are described here.
Methods
This was a multicountry, multicenter, retrospective chart
review study of treatment patterns and clinical outcomes in
a subset of patients with aSTS who received pazopanib as
part of the NPP. Prior to study conduct, ethics approvals
were obtained in line with country-specific national regula-
tions (further details provided in Supplementary section 1).
Supplementary Figure 1 shows an overview of the patient
identification, sampling and subject enrollment processes.
The pazopanib NPP included patients who were 18 years
or older, with aSTS, with an Eastern Cooperative Oncology
Group (ECOG) performance status (PS) of 0 or 1, with
adequate organ system function and clinically normal cardiac
function and had received prior systemic chemotherapy ther-
apy for advanced disease unless it was considered unsuitable.
Patients could not be treated concurrently with another anti-
cancer therapy. Patients with STS histologies excluded from
the PALETTE study were ineligible. Using a convenience sam-
ple of centers with higher numbers of NPP patients, all avail-
able patients from these study centers were included in the
SPIRE study.
The primary objectives were to describe the number and
type of prior and subsequent systemic treatments given to
patients with aSTS who received pazopanib and to determine
pazopanib treatment duration. Secondary objectives included
relative dose intensity, dose modifications and reason for
dose modifications, treatment discontinuation and reason for
discontinuations for patients. Other outcomes of interest
included PFS, OS, clinical benefit rate (complete response
[CR]þpartial response [PR]þ stable disease [SD]þpatients
receiving pazopanib for 12 weeks with unknown/undocu-
mented benefit), AEs (measured by Common Terminology
Criteria for Adverse Events (CTCAE) version 3.0 or 4.0), and
reasons for treatment discontinuation. PFS and OS were esti-
mated by the Kaplan–Meier method. The analysis was mainly
descriptive with appropriate statistical methods, further
details are provided in the Supplementary section 1.
Results
The data were collected from patient medical charts for
patients who received pazopanib between 26th August 2011
and 1st August 2013. The study was conducted at 24 sites
across six countries (Australia, Greece, Israel, Italy, the
Netherlands and the United Kingdom). The median study
period from pazopanib initiation to date of death or date
patient was last known to be alive was 6.9 months. The
mean time from first diagnosis of aSTS until initiation of
pazopanib therapy was 27.3 months.
Patient characteristics
Data were collected on 211 patients out of a total of 531
patients with aSTS who received at least one dose of
pazopanib in the NPP. Supplementary Table 1 shows base-
line patient characteristics where the median age was 56
years, all patients had stage IV (i.e., metastatic) disease,
and the majority of patients had lung metastases (74%,
155/211).
The largest subset of histological subtypes was leio-
myosarcoma (LMS) (41%, 87/211) which included uterine
LMS, nonuterine LMS and LMS of unknown location. The
second and third largest histological subtypes were syn-
ovial sarcoma (11%, 24/211) and undifferentiated sarcoma
(9%, 19/211).
Treatment patterns and pazopanib treatment
Overall in the total observed population of 211 patients, 6%
of patients (13/211) received pazopanib as a first-line ther-
apy, while 28% (59/211), 28% (60/211), 19% (41/211) and
19% (39/211) received pazopanib as a second-, third-, fourth-
and fifth-line or above therapy on the NPP, respectively. The
frequencies of treatment, including pazopanib and other sys-
temic therapies, by the line of therapy, are described in
Figure 1. Thirty-nine percent (39%) of patients (83/211)
received trabectedin either before or after pazopanib, 66%
(55/83) of which had leiomyosarcoma.
The mean daily dose of pazopanib was 715mg, which
translates to a mean relative dose intensity of 92% (Table 1).
The mean starting daily dose was 738mg, the majority of
patients (179, 84.8%) started at a daily dose of 800mg with
24 patients (11.4%) starting at daily doses 50% of the
labeled dose of 800mg/day. Twenty-two percent (47/211) of
patients had at least one dose reduction and 20% (42/211) of
patients experienced at least one dose interruption. The rea-
sons for either a dose reduction or interruption were: non-
serious AEs (65%, 58/89); serious AEs (14%, 12/89); patient’s
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decision unrelated to AE (10%, 9/89) and other (11%, 10/89).
The main AEs leading to dose reductions included hyperten-
sion (3%, 6/211), diarrhea and nausea (2%, 5/211 each) and
fatigue (1%, 3/211).
At the end of the study, 40% (84/211) of patients were
still alive and of those patients still alive, 18% (15/84)
remained on pazopanib. Reasons for pazopanib discontinu-
ation are shown in Supplementary Figure 2, with the majority
of patients (67%, 140/211) discontinuing due to disease
progression.
The median treatment duration for pazopanib was 3.1
months (95% CI: 2.8–3.8) (Table 2(A)). There was considerable
variation in treatment duration by histological subtype, with
some patients remaining on therapy for an extended
duration and other patients coming off therapy quickly
(Table 2(A) and Supplementary Figure 2), although some of
the histological subtypes had small numbers of patients.
However, it was notable that some patients across most
histological subtypes stayed on therapy for an extended dur-
ation. The histological subtypes with the longest median
treatment duration included: PEComa (8.2 months);
aggressive fibromatosis (8.0 months); alveolar soft part sar-
coma (7.1 months); desmoplastic small round cell tumor (5.7
months) and synovial sarcoma (5.1 months). Treatment dur-
ation also varied by ECOG PS, with the longest median treat-
ment duration occurring in patients with a PS of 0 (4.5
months), followed by a PS of 1 (2.2 months), while patients
with a PS of 2þ had a median treatment duration of 1.3
months and those of unknown PS had a median treatment
duration of 3.3 months (Table 2(B)). The relationship between
the PS and line of pazopanib therapy is shown in
Supplementary Table 3(C), with patients with PS 0/1 receiving
pazopanib across a range of therapy lines.
Effectiveness evaluations
Of the 211 patients, a clinical benefit at any time was experi-
enced in 46% (97/211) of patients. Clinical benefit was
observed in 62% (8/13) of first-line, 48% (28/59) of 2nd-line,
37% (22/60) of third-line, 58% (23/40) of fourth-line therapy
and in 41% (16/39) of patients receiving pazopanib as a fifth-
line therapy.
No CRs were observed. Patients with undifferentiated sar-
coma (not otherwise specified (NOS)) had the highest per-
centage of PRs (26%, 5/19). Histological subtypes with the
highest percentage of clinical benefit at any time, in sample
sizes >10, included: nonuterine LMS (45%, 18/40) and uterine
LMS (43%, 17/40), synovial sarcoma (54%, 13/24), undifferen-
tiated sarcoma (NOS) (42%, 8/19), angiosarcoma (38%, 6/16)
and solitary fibrous tumors (54%, 7/13) (Table 2(A)). In groups
with smaller sample sizes (5n> 10), 85% (4/5) of patients
with desmoplastic small round cell tumors and 71% (5/7) of
Table 1. Pazopanib average daily dose and relative dose intensity.
N¼ 211
Mean average daily dose (mg) 714.8
Mean relative dose intensity (%) 92.2
Mean starting dose (mg) 738.4
Starting dose (mg), n (%)
200 9 (4.3)
400 15 (7.1)
600 8 (3.8)
800 179 (84.8)
Other 0
Figure 1. Treatment regimens by line of therapy (observed population). There are 67 patients who had 5th line or above which ¼129 regimens.
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patients with LMS (of unknown location) experienced clinical
benefit with pazopanib.
The median PFS was 3.0 months (95% CI: 2.7–3.5) (Table 3
and Supplementary Figure 3(A)). PFS decreased with a poorer
PS, similar outcomes were observed for the PFS relating to
each line therapy (Table 3). Median OS from first palliative
treatment was 31.6 months (95% CI: 24.9–35.4) and from ini-
tiation of pazopanib therapy was 11.1 months (95% CI: 7.
8–13.8) (Table 3, Supplementary Figure 3(B)).
The OS from time of pazopanib initiation varied by histo-
logical subtypes, where the median OS (months) was similar
for subjects with nonuterine LMS (12.9, CI: 6.1–17.3), synovial
sarcoma (13.8, CI: 8.8–) and solitary fibrous tumor (13.2, CI:
4.5–25.7) and appears slightly longer for subjects with uterine
LMS (16.5, CI: 5.5–24.7) and leiomyosarcoma of unknown
location (17.6, CI: 4.7–NR) (Supplementary Table 4).
Adverse events
The most common AEs (>10%) with pazopanib (any grade)
included: gastrointestinal disorders (i.e., diarrhea, nausea,
vomiting, etc.) (28%, 60/211); general disorders (i.e., fatigue,
asthenia, etc.) (27%, 56/211); skin and subcutaneous
tissue disorders (18%, 38/211); and vascular disorders (i.e.,
hypertension, DVT and flushing) (11%, 24/211); however,
none of these were of CTCAE version 4 grade 4 or 5 severity.
Table 4 shows the AEs of special interest. Thirteen percent
(27/211) of patients discontinued due to AEs (Supplementary
Table 5).
Discussion
The results of this retrospective chart review study demon-
strate the activity of pazopanib in a mostly heavily pretreated
aSTS patient population. The median duration of treatment
of 3.1 months reflects the underlying condition of the
Table 2A. Pazopanib treatment duration and clinical benefit by histological subtype.
Total (N)
Median Treatment
Durationa (months)
[95% CI]b
Tx Duration
Min
Tx Duration
Maxd Cen-sored n CRc PRc SDc
12w Tx,
UNKc
<12w Tx,
UNKc PDc
All Subtypes 211 3.1 [2.8, 3.8] 0.0 29.7þ 22 0 15 38 44 28 86
Leiomyosarcoma (LMS), nonuterine 40 3.2 [2.2, 4.5] 0.0 23.2þ 5 0 3 6 9 6 16
Leiomyosarcoma (LMS), uterine 40 2.8 [2.2, 3.7] 0.5 20.0 2 0 1 5 12 4 18
Synovial sarcoma 24 5.1 [3.8, 6.3] 0.0 16.6þ 2 0 1 6 6 1 10
Undifferentiated sarcoma (NOS) 19 2.4 [1.4, 5.5] 0.0 24.2þ 5 0 5 1 2 3 8
Angiosarcoma 16 2.6 [1.8, 5.5] 0.4 15.5þ 1 0 2 2 2 2 8
Solitary fibrous tumor 13 4.7 [1.7, 11.9] 0.3 21.1þ 1 0 0 5 2 3 3
Leiomyosarcoma (LMS),
unknown location
7 3.5 [2.3, 5.1] 1.2 7.4 0 0 0 2 3 1 1
Hemangioendothelioma 6 1.8 [1.3, 3.1] 0.6 9.3 0 0 0 0 2 1 3
Desmoplastic small round cell tumor 5 5.7 [0.5, 9.3] 0.5 9.3 0 0 1 3 0 0 1
Fibrosarcoma 5 2.9 [0.4, 21.2] 0.4 21.2 0 0 0 1 0 1 3
Malignant peripheral nerve
sheath tumor (MPNST)
5 3.6 [0.5, 14.0] 0.5 14.0 0 0 0 0 2 1 2
Myxofibrosarcoma 5 3.6 [0.1, –] 0.0 26.7þ 2 0 1 0 1 1 2
Epithelioid sarcoma 4 1.9 [1.4, –] 1.4 25.4þ 1 0 0 1 0 1 2
Fibromyxoid sarcoma 3  [2.8, –] 2.8 29.7þ 2 0 0 2 0 0 1
Rhabdomyosarcoma 3 0.6 [0.1, 3.0] 0.1 3.0 0 0 0 0 1 1 1
Spindle cell sarcoma 3 1.7 [1.1, 2.1] 1.1 2.1 0 0 0 0 0 0 3
Endometrial stromal cell sarcoma 2 1.4 [0.5, 2.2] 0.5 2.2 0 0 0 0 0 1 1
Fibromatosis 2 8.0 [3.8, 12.2] 3.8 12.2 0 0 0 1 1 0 0
PEComa 2 8.2 [6.8, 9.7] 6.8 9.7 0 0 0 1 1 0 0
Alveolar soft part sarcoma 1 7.1 [–, –] 7.1 7.1 0 0 0 1 0 0 0
Clear cell sarcoma 1 1.2 [–, –] 1.2 1.2 0 0 0 0 0 1 0
Mesenchymal sarcoma 1  [–, –] 25.2 25.2þ 1 0 0 1 0 0 0
Sarcomatoid carcinoma 1 2.1 [–, –] 2.1 2.1 0 0 0 0 0 0 1
aBased on Kaplan–Meier estimates.
bUsing the methodology of Brookmeyer and Crowley.
cBased on the number of patients treated with pazopanib overall and for each histological listed in the table.
dþCensored maximum treatment duration (treatment ongoing or end date unknown); N¼number of observations.
CR: complete response; PR: partial response; SD: stable disease; PD: progressive disease; CI: confidence interval; PEComa: Neoplasms with perivascular epithelioid
cell differentiation; tx: treated; w: weeks.
Table 2B. Treatment duration by performance status (PS).
Performance status N Median treatment duration (months) [95% CI]
PS 0 41 4.5 [3.3, 5.9]
PS 1 47 2.2 [1.9, 3.1]
PS 2þ 9 1.3 [1.1, 2.3]
PS unknown 114 3.3 [2.8, 4.9]
CI: confidence interval; N: number of observations; PS: performance status.
Table 3. Progression-free survival (PFS) and overall survival (OS) for pazopanib
therapy and survival status at end of study.
Total (N¼ 211)
Median PFS, in months [95% CI]
Overall 3.0 [2.7, 3.5]
By performance status (PS)
PS 0 3.9 [3.2, 5.6]
PS 1 2.5 [2.0, 2.9]
PS 2þ 1.1 [0.3, 1.3]
PS Unknown 3.5 [2.8, 4.4]
By line of therapy
2nd line 3.1 [2.2, 5.0]
3rd line 2.5 [1.8, 2.9]
4th line 3.7 [3.1, 5.3]
5th lineþ 2.8 [2.3, 4.2]
Median OS, in months [95% CI]
From initiation of pazopanib therapy 11.1 [7.8, 13.8]
From 1st palliative treatment 31.6 [24.9, 35.4]
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patients receiving pazopanib therapy in this compassionate
use setting, including patients that are quite often in poorer
condition than in clinical studies, and receiving treatments
that are not fully aligned with ESMO guidelines [6] and there-
fore needs to be interpreted accordingly. Median treatment
duration of pazopanib therapy varied considerably both by,
and within, histological subtype.
Effectiveness was observed across a wide range of histo-
logical subtypes as demonstrated by extended duration of
therapy in some patients, across most histological subtypes.
While some patients having prolonged treatment were suf-
fering from diseases with an indolent pattern of disease pro-
gression, for example, alveolar soft part sarcoma, the median
duration of treatment in synovial sarcoma (5.1 months,
n¼ 24) and desmoplastic small round cell tumor (5.7 months,
n¼ 5), both aggressive, rapidly progressing diseases, is note-
worthy. The small numbers make it difficult to draw firm con-
clusions about any specific subtype. It should also be noted
that fibromatosis (n¼ 2) and sarcomatoid carcinoma (n¼ 1)
are not strictly sarcomas, fibromatosis because it is a clonal
connective tissue tumor that does not metastasize, but can
be locally aggressive and occasionally fatal, and sarcomatoid
carcinoma because it has epithelial differentiation but never-
theless may behave like a sarcoma and is often treated as
one. However, these results are in accordance with previous
publications in several case series of patients which have
shown some patients with certain subtypes benefit from
using pazopanib, including LMS, synovial sarcoma, angiosar-
coma, UPS, MPNST, SFT, epithelioid hemangioendothelioma,
hemangiopericytoma, rhabdomyosarcoma, desmoplastic
small round cell and desmoid tumor/aggressive fibromatosis
[15–27]. Overall, in this study, 46% of patients experienced
clinical benefit at any time while on pazopanib. However, it
should be noted that response rate and PFS can be difficult
to measure in the context of a retrospective study due to
heterogeneity in scanning frequency and incomplete infor-
mation in medical charts. The 1.3 month (range 1.1–2.3)
treatment duration in ECOG PS 2þ patients echoes the lim-
ited role of chemotherapy in aSTS in these patients [28].
Many patients (54%) had unknown PS in this study because
this variable was not recorded in the medical charts.
However, it is likely that this unknown PS was 0 or 1, aligned
with the NPP recruitment requirements.
This NPP was not a controlled prospective clinical trial,
and therefore, the experience with pazopanib in this study
represents real-world effectiveness and safety of pazopanib
used in a compassionate use setting in a heavily pretreated
aSTS population. In addition, the absence of central radio-
logical and pathological review due to the retrospective chart
review methodology contributes uncertainty toward the out-
comes reported here. The median OS (11.1 months) and PFS
(3.0 months) observed supplement the results observed in
the rigidly controlled phase-III PALETTE clinical trial study (OS
of 12.5 months and PFS of 4.6 months), demonstrating that
the activity with pazopanib translates into the compassionate
use setting. It is important to remember that the effective-
ness of the drug must be balanced with its cost [29].
The extent and nature of the adverse events were consist-
ent with the known safety profile of pazopanib with 13% of
patients discontinuing due to adverse events [5,8,10,11,13].
The adverse events that occurred were typically managed by
temporary dose reductions of pazopanib. Although fewer AEs
were reported in this study compared with PALETTE, this
could be related to the retrospective nature of the study, as
not all AEs may be fully captured in the charts. The tolerabil-
ity of pazopanib was reassuring with a 92% relative dose
intensity achieved, allowing most patients to receive close to
the full 800mg daily dose. However, this figure could have
been influenced by failure to record all dose changes in the
medical chart.
The results from the SPIRE study support the information
generated from clinical trials showing pazopanib to be active
in heavily pretreated patients and specifically after previous
chemotherapy failure [11,13]. In this study, from a compas-
sionate use program, 66% (139/211) of patients received
pazopanib as a third or later line of therapy. Interestingly,
many patients receiving treatment in the fourth line and fifth
line and beyond setting still experienced a clinical benefit
with pazopanib. In the present study, there was a distinct dif-
ference in treatment patterns for first-line compared to
second and later lines of therapy. The dominant first-line
treatment regimens were anthracyclines with or without ifos-
famide, which is consistent with the recommendations in the
guidelines for the treatment of aSTS, although this was also
a prerequisite according to the eligibility criteria [6]. In the
second- and later-line settings, pazopanib was the dominant
treatment regimen.
At time of chart abstraction for the SPIRE study, the
majority of patients (60%, 127/211) received no further sys-
temic treatment. Eighteen percent (15/84) of patients alive at
the time of chart abstraction continued with pazopanib
therapy.
Table 4. Adverse events of special interest while on pazopanib therapy.
N¼ 211 Severity (CTCAE grades), n (%)
Category of AESI Grade 1 Grade 2 Grade 3 Grade 4 Grade 5 Unknown Total
Diarrhea 22 (10.4) 11 (5.2) 0 0 0 6 (2.8) 39 (18.5)
Nausea 13 (6.2) 8 (3.8) 6 (2.8) 0 0 6 (2.8) 33 (15.6)
Vomiting 6 (2.8) 5 (2.4) 2 (0.9) 0 0 9 (4.3) 22 (10.4)
Tumor pain 1 (0.5) 1 (0.5) 2 (0.9) 0 0 4 (1.9) 8 (3.8)
Pneumothorax 0 2 (0.9) 2 (0.9) 0 0 0 4 (1.9)
Heart/cardiac failure 0 0 1 (0.5) 0 1 (0.5) 0 2 (0.9)
Pulmonary Embolism 0 0 0 0 1 (0.5) 1 (0.5) 2 (0.9)
DVT 0 1 (0.5) 0 0 0 0 1 (0.5)
AESI: adverse events of special interest; CTCAE: Common Terminology Criteria for Adverse Events version 3.0 or 4.0: 1¼mild; 2¼moderate; 3¼ severe; 4¼ life-
threatening; 5¼ fatal; DVT: deep vein thrombosis.
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Conclusions
The SPIRE study is one of the first datasets describing the
activity of pazopanib in patients with aSTS outside of a clin-
ical trial setting, building on the evidence from the small ser-
ies of specific histological subtypes previously reported.
Activity was evident across a wide range of histological sub-
types which was encouraging in the context of this rare, het-
erogeneous group of diseases. No new safety concerns were
noted and pazopanib was well tolerated with a dose inten-
sity of 92%, equating to 715mg daily dose. It is important to
consider that this study was conducted in a patient popula-
tion that received treatment exclusively in a compassionate
use setting where patients typically have received multiple
lines of treatment and have limited therapeutic options.
Despite this, the data are reassuring and complement the
existing clinical trial data, supporting the use of pazopanib in
routine clinical practice.
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